2seventy bio, Inc. (TSVT)
(Delayed Data from NSDQ)
$4.40 USD
+0.06 (1.38%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $4.40 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
TSVT 4.40 +0.06(1.38%)
Will TSVT be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for TSVT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TSVT
Should Bristol Myers Stock Be in Your Portfolio Pre-Q3 Earnings?
Strength Seen in Castle Biosciences (CSTL): Can Its 9.4% Jump Turn into More Strength?
TSVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study
Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated
2seventy bio, Inc. (TSVT) Reports Q2 Loss, Lags Revenue Estimates
Other News for TSVT
Bristol-Myers raises outlook ahead of consensus after Q3 beat
Notable Two Hundred Day Moving Average Cross - TSVT
TD Cowen Sticks to Its Hold Rating for 2seventy bio (TSVT)
Europe Drug Regulator's Advising Panel Recommends Approval Of Novo Nordisk's Australia-Approved Hemophilia Drug
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance